Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07546357 · ClinicalTrials.gov registry record · NA
AIManage Using an AI-driven CDS and Chatbot
A NA study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT07546357: Clinical Trial NA study, sponsored by NYU Langone Health.
NCT07546357 is a NA study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07546357, a NA study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
Primary Outcome
In Phase 1, qualitative data regarding perceived usefulness will be collected.
Interventions
- OTHER AIManage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2029-03-30 |
| Phase | NA |
What is known before NCT07546357 opens enrollment
NCT07546357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which AIManage is the first listed.
NCT07546357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07546357 about?
NCT07546357 is a clinical study titled "AIManage Using an AI-driven CDS and Chatbot". The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at ...
What is the current status of trial NCT07546357?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2026-06-01. Estimated completion is 2029-03-30.
What interventions are being tested in trial NCT07546357?
The interventions under investigation include: AIManage (OTHER).
Who is sponsoring clinical trial NCT07546357?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07546357's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI